Camber Pharmace Patent-Cliff Exposure & CMS Drug Spending Portfolio

Camber Pharmace (US): 6 reconciled FDA prescription therapies, $26.2M 2024 CMS Part D & Medicaid spend, and $1,411 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$26.2M
2024 Medicare Part D Spend$23.5M
2024 Medicaid Spend$2.7M
California HCAI SB 17 FilingsSpecialty launch notice ($1,411 intro WAC)